Today the National Cancer Institute signed an agreement with Foundation Medicine, Inc., that will greatly increase the size of the Genomic Data Commons (GDC). The addition of data from 18,000 patients in the FoundationOne database to the GDC will provide the research community with more statistical power in their studies and will work toward building a smarter knowledge base.
Foundation Medicine, Inc., is a molecular profiling company that developed FoundationOne, a commercially available cancer profiling test that identifies known genetic alterations in cancer and potential therapeutic opportunities. The data in the FoundationOne dataset that will be submitted to the GDC contains information on the key genetic alterations of a large number of cancer patients and all patient information has been de-identified to protect patient privacy.
from Cancer via ola Kala on Inoreader http://ift.tt/293Jybz
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου